Low-dose UVA1 Radiation in Cutaneous Lupus Patients

Status Completed

Clinical Trial Summary

The investigators are conducting an open-label clinical trial determining the effects of UVA1 phototherapy on cutaneous lupus (CLE) patients. Past research on systemic lupus (SLE) subjects indicates that this treatment is likely to be effective in treating cutaneous lupus with few side effects. The fact that most CLE patients are seen at dermatology clinics also increases the usefulness of this study because there is a large probability that phototherapy treatment will be accessible for many of the patients that stand to benefit from it.

Clinical Trial Description

Study subjects will receive low dose (20 J/cm2) UVA1 phototherapy treatment three times per week for 10 weeks. Each treatment will take less than 30 minutes. This period will be followed by an eight-week observation phase to assess longer term effects of the treatment. Patients will be assessed for disease activity, and blood studies and photos will be completed prior to, during, and after phototherapy treatment. Optional skin biopsies of affected and unaffected skin will be performed at the beginning and end of the active treatment phase. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01776190
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact
Status	Completed
Phase	N/A
Start date	September 2012
Completion date	September 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00420173` - Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)	N/A
Terminated	`NCT04809623` - Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)	Phase 1
Completed	`NCT01300208` - To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus	Phase 2
Terminated	`NCT01470313` - A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus	Phase 1
Completed	`NCT01146444` - Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)	N/A
Completed	`NCT03134222` - Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)	Phase 2
Completed	`NCT01629784` - Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus	N/A
Completed	`NCT00470912` - Sunscreen RV 2457C in Photoinduced CLE	Phase 3
Completed	`NCT01841619` - IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus	Phase 0
Completed	`NCT00523588` - Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser	Phase 2
Recruiting	`NCT06411106` - Deep Phenotyping of Cutaneous Lupus Erythematosus	N/A
Not yet recruiting	`NCT06015737` - A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus	Phase 3
Terminated	`NCT01498406` - Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus	Phase 2
Completed	`NCT04647708` - Study of M5049 in CLE and SLE Participants	Phase 1
Completed	`NCT03817424` - A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis	Phase 1
Active, not recruiting	`NCT03260166` - Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus	Phase 2
Completed	`NCT00317681` - Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)	Phase 2
Completed	`NCT04781816` - Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus	Phase 2